Back to news

velaglucerase alfa (VPRIV) - Wales

The Association is pleased to announce  velaglucerase alfa (VPRIV®) has been approved as a recommended treatment for Gaucher Disease for use within NHS Wales and within three months of Ministerial approval will be routinely available in the NHS across Wales. 

The Gauchers Association has supported this process by submitting a patient submission paper.  For further information please visit